Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) shares rose 3.1% on Tuesday . The company traded as high as C$3.88 and last traded at C$3.76. Approximately 42,504 shares changed hands during mid-day trading, an increase of 474% from the average daily volume of 7,410 shares. The stock had previously closed at C$3.65.
Eupraxia Pharmaceuticals Stock Up 3.1 %
The business has a fifty day moving average price of C$3.12 and a two-hundred day moving average price of C$2.92.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc, a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis.
Read More
- Five stocks we like better than Eupraxia Pharmaceuticals
- Stock Analyst Ratings and Canadian Analyst Ratings
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- What is a Death Cross in Stocks?
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
